Abstract
Dabigatran anticoagulation therapy in patients with chronic kidney disease can be challenging. Progress of renal insufficiendy leads to prolonged drug elimination and thus higher levels of dabigatran serum.
In addition, patients over 75 years of age have higher levels of the drug in serum than younger patients using the same dose.